KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities: 2020-2025

  • Esperion Therapeutics' Other financing activities was N/A to $7.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $29,000 for FY2024, which is 38.10% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Other financing activities of $7.5 million as of Q1 2025, which was up 178.15% from -$9.6 million recorded in Q4 2024.
  • In the past 5 years, Esperion Therapeutics' Other financing activities ranged from a high of $9.6 million in Q3 2024 and a low of -$9.6 million during Q4 2024.
  • For the 3-year period, Esperion Therapeutics' Other financing activities averaged around $1.9 million, with its median value being $3.8 million (2023).
  • Per our database at Business Quant, Esperion Therapeutics' Other financing activities spiked by 338.00% in 2022 and then tumbled by 45,800.00% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Other financing activities (Quarterly) stood at $390,000 in 2021, then soared by 338.00% to -$438,000 in 2022, then skyrocketed by 104.79% to $21,000 in 2023, then crashed by 45,800.00% to -$9.6 million in 2024, then reached $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q1 2025, -$9.6 million for Q4 2024, and $9.6 million during Q3 2024.